SAVSU Technologies Provides Performance Update on evo® Cold Chain 2.0™ System in ImmunoCellular Therapeutics Phase 3 Glioblastoma Cell Therapy Clinical Trial

ALBUQUERQUE, N.M., Feb. 14, 2017 /PRNewswire/ -- SAVSU Technologies, the leading developer of smart precision shipping containers and cloud based cold chain management SaaS solutions, today announced that its evo® Cold Chain 2.0™ live cell visibility platform has been successfully deployed in ImmunoCellular Therapeutics' phase 3 clinical trial of ICT-107, a patient-specific, dendritic cell-based immunotherapy for newly diagnosed glioblastoma. The ICT-107 trial (NCT02546102) will enroll up to 120 clinical sites in the US, Canada and Europe.

Marta Schilling, Vice President, Cell Therapy Manufacturing, commented, "We have been extremely pleased with the performance of the evo® Cold Chain 2.0™ system for use in our phase 3 study. The unique uni-directional packout prevents errors in packaging and makes it very simple for our clinical sites to package the starting apheresis product for shipment to our manufacturing facilities. Validation of tight temperature stability in every shipment is critical, and we have not experienced any temperature or packaging deviations since switching to evo®. It is clear that an enormous amount of thought and testing went in to the design of the evo® system."

Bruce McCormick, President of SAVSU Technologies remarked, "Our optimized technologies represent the next generation of integrated, cloud-connected cold chain technologies. It is rewarding to see the stellar real-world performance of evo® in a high volume, challenging application.  We are committed to supporting ImmunoCellular Therapeutics and the regenerative medicine industry with disruptive products by driving a paradigm shift away from traditional, risk-laden cold chain practices based on the use of poor performing shipping containers and disconnected data systems." 

BioLife Solutions (NASDAQ:BLFS), the leading provider of clinical grade CryoStor^® and HypoThermosol^® biopreservation media for cells and tissues, is an equity partner in SAVSU Technologies and markets and supports the evo® Cold Chain 2.0™ system in the regenerative medicine market.

Chain Link Research and Pharmaceutical Commerce market research estimate that there are 80 million to 130 million annual temperature sensitive pharmaceutical shipments requiring cold chain management, resulting in $12 billion spent annually on cold chain logistics, with $9 billion for transportation and $3 billion for specialized tertiary packaging and instrumentation such as insulated boxes, blankets, phase change materials, temperature sensors and dataloggers. The use of currently available cold technologies results in $15 billion to $35 billion spent annually replacing products lost due to temperature excursions.

About SAVSU Technologies

SAVSU is a leading designer and manufacturer of innovative high performance cloud-connected passive storage and transport containers for temperature sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials. For more information please visit www.savsu.com.

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, has been initiated. ImmunoCellular's pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To learn more about ImmunoCellular, please visit www.imuc.com.

SOURCE SAVSU Technologies